Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions

Leukemia Research

Volumn 38, Issue 5, 2014, Pages 545-550

  Cui, Rui ^a   Gale, Robert Peter ^b   Zhu, Guoqing ^a   Xu, Zefeng ^a   Qin, Tiejun ^a   Zhang, Yue ^a   Huang, Gang ^c   Li, Bing ^a   Fang, Liwei ^a   Zhang, Hongli ^a   Pan, Lijuan ^a   Hu, Naibo ^a   Qu, Shiqiang ^a   Xiao, Zhijian ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Hematopoiesis; Iron metabolism; Myelodysplastic syndromes

Indexed keywords

HEMATOPOIESIS; IRON METABOLISM; MYELODYSPLASTIC SYNDROMES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEPCIDINS; HOMEOSTASIS; HUMANS; IRON; IRON OVERLOAD; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 84899097213     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.01.016     Document Type: Article

References (26)

1. Tefferi A., Vardiman J.V. Myelodysplastic syndromes. N Eng J Med 2009, 361:1872-1875.
2. Sanz G.F., Sanz M.A., Vallespi T., Cañizo M.C., Torrabadella M., García S., et al. Two progression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989, 74:395-408.
3. Cortelezzi A., Cattaneo C., Cristiani S., Duca L., Sarina B., Deliliers G.L., et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?. Hematol J 2000, 1:153-158.
4. Santini V., Girelli D., Sanna A., Martinelli N., Duca L., Campostrini N., et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One 2011, 6:e23109.
5. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
6. Ganz T., Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011, 62:347-360.
7. Tanno T., Bhanu N.V., Oneal P.A., Goh S.H., Staker P., Lee Y.T., et al. High levels of GDFl5 in thalassemia suppress expression of the iron regulatory protein hepeidin. Nat Med 2007, 13:1096-1101.
8. Eling T.E., Baek S.J., Shim M., Lee C.H. NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 2006, 39:649-655.
9. Tamary H., Shalev H., Perez-Avraham G., Zoldan M., Levi I., Swinkels D.W., et al. Elevated growth differentiation factor 15 expressionin patients with congenital dyserythropoietic anemia type I. Blood 2008, 112:5241-5244.
10. Casanovas G., Swinkels D.W., Altamura S., Schwarz K., Laarakkers C.M., Gross H.J., et al. Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II. J Mol Med (Berl) 2011, 89:811-816.
11. Finkenstedt A., Bianchi P., Theurl I., Vogel W., Witcher D.R., Wroblewski V.J., et al. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol 2009, 144:789-793.
12. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumors of haematopoietic and lymphoid tissues 2008, IARC, Lyon. 4th ed.
13. Greenberg P., Cox C., LeBeau M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
14. Bozzini C., Campostrini N., Trombini P., Nemeth E., Castagna A., Tenuti I., et al. Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE hemochromatosis. Blood Cells Mol Dis 2008, 40:347-352.
15. Swinkels D.W., Girelli D., Laarakkers C., Kroot J., Campostrini N., Kemna E.H., et al. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One 2008, 3:e2706.
16. Nie L., Li L., Yang L., Xiao Z. HFE genotype and iron metabolism in Chinese patients with myelodysplastic syndromes and aplastic anemia. Ann Hematol 2010, 89:1249-1253.
17. Zipperer E., Post J.G., Herkert M.S., Kündgen A., Fox F., Haas R., et al. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome. Ann Hematol 2013 July 11, [Epub ahead of print].
18. Cui R., Gale R.P., Xu Z., Qin T., Fang L., Zhang H., et al. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts. Leuk Res 2012, 36:1428-1433.
19. Ambaglio I., Malcovati L., Papaemmanuil E., Laarakkers C.M., Della Porta M.G., Gallì A., et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica 2013, 98:420-423.
20. Ramirez J.M., Schaad O., Durual S., Cossali D., Docquier M., Beris P., et al. Growth diferentiation factor 15 production is necessaryfor normal erythroid diferentiation and is increased in refractory anaemia with ring sideroblasts. Br J Haematol 2009, 144:251-262.
21. Pinto J.P., Ribeiro S., Pontes H., Thowfeequ S., Tosh D., Carvalho F., et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood 2008, 111:5727-5733.
22. Nicolas G., Chauvet C., Viatte L., Danan J.L., Bigard X., Devaux I., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002, 110:1037-1044.
23. Liu Q., Davidoff O., Niss K., Haase V.H. Hypoxia inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest 2012, 122:4635-4644.
24. Tanno T., Porayette P., Sripichai O., Noh S.J., Byrnes C., Bhupatiraju A., et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009, 114:181-186.
25. Gattermann N., Rachmilewitz E.A. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 2011, 90:1-10.
26. Ghoti H., Fibach E., Merkel D., Perez-Avraham G., Grisariu S., Rachmilewitz E.A. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-over loaded patients with myelodysplastic syndromes. Haematologica 2010, 95:1433-1434.